NeuroBo Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NeuroBo Pharmaceuticals generated cash of -$10,799,000, which is more than the previous year. Cash used in financing activities reached the amount of -$80,000 last year. Net change in cash is therefore -$10,929,000.
Cash Flow
| 2014 | -195K | 0 | 509K |
|---|---|---|---|
| 2015 | -5.43M | 0 | 8.73M |
| 2016 | -11.04M | 0 | 31.45M |
| 2017 | -26.90M | 0 | 21.34M |
| 2018 | -21.91M | 0 | 22.39M |
| 2019 | -7.03M | -6.05M | 24.16M |
| 2020 | -10.76M | 69K | 6.85M |
| 2021 | -15.13M | -586K | 22.02M |
| 2022 | -11.71M | 8K | 28.68K |
| 2023 | -10.79M | -50K | -80K |
NRBO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 33.36M | 16.38M | 10.08M | 13.92M | 2.84M | 18.47M | 24.03M | 3.62M | 317K | 3K |
Operating activities | ||||||||||
Net income | -12.47M | -13.96M | -15.28M | -29.67M | -21.31M | -23.63M | -33.41M | -14.58M | -9.02M | -320K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6K | 20K | 48K | 46K | 17K | 346K | 137K | -17K | 0 | 0 |
Stock-based compensation expense | 222K | 854 | 662K | 699K | 118 | 0 | 5.27M | 1.71M | 284K | 53K |
| Deferred income tax benefit | 222K | 854 | 662K | 699K | 118 | 0 | 5.27M | 1.71M | 284K | 53K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 113K | -202K | -1.16M | 1.12M | -1.04M | -1.98M | 2.00M | 1.47M | 444K | -6K |
Cash generated by operating activities | -10.79M | -11.71M | -15.13M | -10.76M | -7.03M | -21.91M | -26.90M | -11.04M | -5.43M | -195K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -50K | 0 | -3K | -4K | -214K | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 8K | -583 | 180K | 1.52M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -50K | 8K | -586K | 69K | -6.05M | 0 | 0 | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | -80K | 32.25M | 24M | 7.5M | 24.24M | 25.15M | 12.54M | 30.27M | 3K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | -741K | 10M | 0 | 7.41M | 0 |
Cash used in financing activities | -80K | 28.68K | 22.02M | 6.85M | 24.16M | 22.39M | 21.34M | 31.45M | 8.73M | 509K |
Net Change In Cash | -10.92M | 16.97M | 6.29M | -3.83M | 11.07M | 481K | -5.56M | 20.41M | 3.30M | 314K |
Cash at end of period | 22.43M | 33.36M | 16.38M | 10.08M | 13.92M | 18.95M | 18.47M | 24.03M | 3.62M | 317K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |